Hepatitis C: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
imported>Robert Badgett
mNo edit summary
Line 4: Line 4:
==Treatment==
==Treatment==
{| class="wikitable"
{| class="wikitable"
|+ [[Randomized controlled trial]]s of [[protease inhibitors]] for hepatitis C genotype 1 infection.
|+ [[Randomized controlled trial]]s of [[protease inhibitor]]s against the NS3/4A serine protease for hepatitis C genotype 1 infection.
<ref name="pmid21696308">{{cite journal| author=Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S et al.| title=Telaprevir for retreatment of HCV infection. | journal=N Engl J Med | year= 2011 | volume= 364 | issue= 25 | pages= 2417-28 | pmid=21696308 | doi=10.1056/NEJMoa1013086 | pmc= | url= }} </ref>
<ref name="pmid21696308">{{cite journal| author=Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S et al.| title=Telaprevir for retreatment of HCV infection. | journal=N Engl J Med | year= 2011 | volume= 364 | issue= 25 | pages= 2417-28 | pmid=21696308 | doi=10.1056/NEJMoa1013086 | pmc= | url= }} </ref>
<ref name="pmid21696307">{{cite journal| author=Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al.| title=Telaprevir for previously untreated chronic hepatitis C virus infection. | journal=N Engl J Med | year= 2011 | volume= 364 | issue= 25 | pages= 2405-16 | pmid=21696307 | doi=10.1056/NEJMoa1012912 | pmc= | url= }} </ref>
<ref name="pmid21696307">{{cite journal| author=Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al.| title=Telaprevir for previously untreated chronic hepatitis C virus infection. | journal=N Engl J Med | year= 2011 | volume= 364 | issue= 25 | pages= 2405-16 | pmid=21696307 | doi=10.1056/NEJMoa1012912 | pmc= | url= }} </ref>

Revision as of 09:23, 13 October 2012

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Hepatitis C is "inflammation of the liver in humans caused by hepatitis c virus, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown."[1]

Treatment

Randomized controlled trials of protease inhibitors against the NS3/4A serine protease for hepatitis C genotype 1 infection. [2] [3] [4] [5]
Trial Patients Intervention Comparison Outcome Results
Intervention Control
ADVANCE Study[2]
2011
Previously untreated patients telaprevir peginterferon-ribavirin HCV RNA 24 weeks after last treatment 69% to 75% 44%
REALIZE Study[3]
2011
Previously treated patients telaprevir peginterferon-ribavirin HCV RNA 24 weeks after last treatment 83% to 88% (prior reponse)
54% to 59% (prior partial response)
29% to 33% (prior non-response)
24% (prior reponse)
15% (prior partial response)
5% (prior non-response)
SPRINT-2 study[4]
2011
Previously untreated patients boceprevir peginterferon-ribavirin HCV RNA level 59% to 66% 21%
HCV RESPOND-2 study[5]
2011
Previously treated patients boceprevir peginterferon-ribavirin HCV RNA level 67% to 68% (nonblack patients)
42% to 53% (black patients)
40% (nonblack patients)
23% (black patients)

Two protease inhibitors, telaprevir and boceprevir may add benefit to standard therapy of genotype 1 infection with peginterferon and ribavirin. Telaprevir adds to peginterferon and ribavirin for previously treated[2] and untreated[3] patients. Boceprevir adds to peginterferon and ribavirin for previously treated[5] and untreated[4] patients.

Screening

The United States Centers for Disease Control and Prevention issued draft recommendation for screening individuals born between 1945 and 1965.[6]

References

  1. Anonymous (2024), Hepatitis C (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. 2.0 2.1 2.2 Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S et al. (2011). "Telaprevir for retreatment of HCV infection.". N Engl J Med 364 (25): 2417-28. DOI:10.1056/NEJMoa1013086. PMID 21696308. Research Blogging.
  3. 3.0 3.1 3.2 Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al. (2011). "Telaprevir for previously untreated chronic hepatitis C virus infection.". N Engl J Med 364 (25): 2405-16. DOI:10.1056/NEJMoa1012912. PMID 21696307. Research Blogging.
  4. 4.0 4.1 4.2 Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS et al. (2011). "Boceprevir for untreated chronic HCV genotype 1 infection.". N Engl J Med 364 (13): 1195-206. DOI:10.1056/NEJMoa1010494. PMID 21449783. Research Blogging.
  5. 5.0 5.1 5.2 Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S et al. (2011). "Boceprevir for previously treated chronic HCV genotype 1 infection.". N Engl J Med 364 (13): 1207-17. DOI:10.1056/NEJMoa1009482. PMID 21449784. Research Blogging.
  6. Centers for Disease Control and Prevention (2012) CDC Announces First Ever National Hepatitis Testing Day and Proposes that All Baby Boomers Be Tested Once for Hepatitis C